Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190593 · ClinicalTrials.gov registry record · Phase 3
Raloxifene Use for The Heart
A Phase 3 study of Cardiovascular Diseases and Breast Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,000
- Enrollment target
- 1
- Study location
NCT00190593 is a Phase 3 study of Cardiovascular Diseases and Breast Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 10,000 participants, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00190593, a Phase 3 study of Cardiovascular Diseases and Breast Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Conditions Studied
Interventions
- DRUG placebo
- DRUG raloxifene
Study Locations (1)
Minnesota
- For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 1998-06 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190593
The ClinicalTrials.gov registry entry for NCT00190593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00190593 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00190593 about?
NCT00190593 is a clinical study titled "Raloxifene Use for The Heart". The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
What is the current status of trial NCT00190593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,000 participants. The study started on 1998-06. Estimated completion is 2005-11.
What conditions does trial NCT00190593 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Breast Neoplasms.
What interventions are being tested in trial NCT00190593?
The interventions under investigation include: placebo (DRUG), raloxifene (DRUG).
Who is sponsoring clinical trial NCT00190593?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190593 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.